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Background: Unsafe injection practices contribute to increased risks of blood-borne infections, including human
immunodeﬁciency virus, hepatitis B and hepatitis C viruses. The aim of this study was to estimate the prevalence
of medical injections as well as assess the level of access to sterile injection equipment by demographic factors
in low- and middle-income countries (LMICs).
Methods: We carried out a meta-analysis of nationally representative Demographic and Health Surveys (DHSs)
conducted between 2010 and 2017 in 39 LMICs. Random effects meta-analysis was used in estimating pooled
and disaggregated prevalence. All analyses were conducted using Stata version 14 and Microsoft Excel 2016.
Results: The pooled 12-month prevalence estimate of medical injection was 32.4% (95% conﬁdence interval
29.3–35.6). Pakistan, Rwanda and Myanmar had the highest prevalence of medical injection: 59.1%, 56.4%
and 53.0%, respectively. Regionally, the prevalence of medical injection ranged from 13.5% in west Asia to
42.7% in south and southeast Asia. The pooled prevalence of access to sterile injection equipment was 96.5%,
with Pakistan, Comoros and Afghanistan having comparatively less prevalence: 86.0%, 90.3% and 90.9%,
respectively.
Conclusions: Overuse of medical injection and potentially unsafe injection practices remain a considerable
challenge in LMICs. To stem the tides of these challenges, national governments of LMICs need to initiate
appropriate interventions, including education of stakeholders, and equity in access to quality healthcare
services.
Keywords: blood-borne infections, low- and middle-income countries, medical injection, sterile injection equipment

Introduction
Injections are one of the most common medical procedures
performed in healthcare settings worldwide.1 About 16 billion
injections are administered annually.1 The majority of these
injections, approximately 90%, are given to administer medicines
for therapeutic purposes, while injections for vaccination and
other procedures such as blood transfusions and injectable contraceptives account for the remaining 10%.1 In many instances
where injections are administered for therapeutic purposes,
they are usually unnecessary or could be replaced by oral

medications.1,2 A number of factors contribute to this overuse,
including the misconception that injections are more effective
than oral medications and the ﬁnancial gains associated with the
use of injections, as they increase the fees healthcare providers
charge for their services.3
A safe injection is one that does not harm the patient receiving
it, does not expose the healthcare provider to any preventable
risk and does not result in waste that is dangerous for the
community.1 Unsafe injection practices such as reusing needles and syringes and poor handling and disposal of used
injection equipment are related to overuse of or unnecessary
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Methods
Data source
This study utilized data from the Demographic and Health Survey
(DHS) reports of LMICs. The DHSs are nationally representative
household surveys conducted by ICF Macro/MEASURE DHS
on behalf of national ministries of health of the respective
countries. The data and reports are freely available and accessible
from the DHS website (https://dhsprogram.com/data/datacollection.cfm). Many international partners, including the US
Agency for International Development, provide ﬁnancial support
for the surveys.15 The standard DHS uses identical methodology
including the probability sampling strategy and survey instrument to collect data that are comparable across countries.15
Our study included reports of countries whose surveys were
conducted from 2010 to 2017 and contained data on the
prevalence of medical injections among adults 15–49 y of age
and access to syringes and needles taken from new, unopened
packages. This study was based on a secondary analysis of
data extracted from DHS reports in LMICs. The variables from
the DHS reports, extracted and included in our analysis, were
the prevalence of medical injection by demographic category,
including sex (male, female), age group (15–24, 25–29, 30–39,
40–49 y), place of residence (rural, urban), education level (no
education, primary, secondary/higher) and wealth index (lowest,
second, middle, fourth, highest). The data in the reports were
completely anonymized. No additional ethical clearance was
required for the conduct of the present study.

Figure 1. PRISMA ﬂow chart for country selection.

Deﬁnition of outcome variables
In the DHS, a medical injection was considered to be an injection
given by a healthcare worker, which can be a doctor, nurse,
pharmacist, dentist or other healthcare professionals. The prevalence of medical injections was estimated as the proportion of
adults who received an injection from a healthcare worker in
the 12 months preceding the survey. Participants in the surveys
were asked if their last injection was given with a new, unopened
syringe package, and responses to this question were used in
estimating access to sterile injection equipment.

Selection of countries and inclusion criteria
The Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines16 were followed in selecting the countries included in this study (Figure 1). Countries
were included if they are classiﬁed as an LMIC by the World
Bank (https://data.worldbank.org/income-level/low-and-middleincome) and had a DHS conducted from 2010 to 2017 with
medical injection indicators.15 This study period was selected to
provide the most recent update on the subject using available
nationally representative data. We excluded from our study
countries without DHS data or whose DHS data did not measure
the prevalence of medical injection.

Data analysis
Data were analysed using Stata version 14 (StataCorp, College
Station, TX, USA) and Excel 2016 (Microsoft, Redmond, WA, USA).
The proportions of participants whose last injection was administered using a syringe from a new, unopened package were also
extracted by demographic category. Countries whose reports
were extracted were classiﬁed by geographic region according
to the DHS regional classiﬁcation (Table 1). Furthermore, we

389

Downloaded from https://academic.oup.com/inthealth/article/12/5/388/5680313 by Serials Acquisitions Edith Cowan University, Library-Level 2 user on 14 September 2021

injections.4–6 These practices portend great health risks for
patients, healthcare workers and the community at large.7 The
health risks include direct exposure to blood-borne diseases
and/or increased chances of needlestick injury and subsequent
exposure to blood-borne infections,2,8,9 all contributing to the
global burden of diseases.10 For instance, available data show
that injection medication is a major contributor to the increasing
trends of new human immunodeﬁciency virus (HIV) infections
in many countries around the world.11,12 Other blood-borne
infections, particularly, hepatitis B virus, hepatitis C virus and
viral haemorrhagic fever viruses, are similarly and commonly
transmitted through unsafe injections.1,2,6,13
In several low- and middle-income countries (LMICs), especially the Eastern Mediterranean and Southeast Asia regions, evidence conﬁrms both unnecessary and unsafe use of
injections.2,3,14 However, little is known about the prevalence
of medical injections and access to sterile injection equipment
in LMICs. Worldwide, the prevalence of unsafe injections was
estimated to have decreased from 39% in 2000 to 5% in 2010.2,5
Conversely, in 2010, up to 1.7 million hepatitis B virus infections,
315 000 hepatitis C virus infections and 33 800 HIV infections
were estimated to have occurred due to unsafe injections.5 The
World Health Organization’s (WHO) report on global hepatitis
identiﬁed the need for more recent data to monitor progress
towards injection safety since 2010.2 Accordingly, we utilized
data from nationally representative household surveys (2010–
2017) to provide an up-to-date estimate of the prevalence of
medical injections and access to sterile injection equipment in
LMICs by demographic factors.

E. O. Adewuyi and A. Auta

Countries

Study period

Sub-Saharan Africa
Benin
2011–2012
Burkina Faso
2010
Burundi
2010
Cameroun
2011
Chad
2014–2015
Comoros
2012
Congo
2011–2012
Cote d’Ivoire
2011–2012
Democratic
2013–2014
Republic of the
Congo
Equatorial Guinea
2011
Ethiopia
2011
Gabon
2012
Gambia
2013
Ghana
2014
Kenya
2014
Lesotho
2014
Liberia
2013
Mali
2012–2013
Mozambique
2011
Namibia
2013
Niger
2012
Nigeria
2013
Rwanda
2014–2015
Sierra Leone
2013
Tanzania
2015–2016
Togo
2013–2014
Uganda
2011
Zambia
2013–2014
Zimbabwe
2015
South and Southeast Asia
Afghanistan
2015
Cambodia
2014
Indonesia
2012
Myanmar
2015–2016
Nepal
2011
Pakistan
2012–2013
West Asia
Armenia
2015–2016
Central Asia
Kyrgyz Republic
2012
Latin America and the Caribbean
Dominican
2013
Republic
Haiti
2012
Overall
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No. of participants

Average injections/ Prevalence of medical
person/year
injection, % (95% CI)

Access to new syringe and
needle, % (95% CI)

21 032
23 587
13 149
13 912
10 900
7328
15 542
14 696
26 582

0.5
0.6
0.9
1.8
1.9
0.6
1.8
1.2
3.3

15.8 (15.3–16.3)
31.6 (31.0–32.2)
33.9 (33.1–34.7)
40.3 (39.5–41.1)
36.0 (35.1–36.9)
20.0 (19.1–20.9)
25.5 (24.8–26.1)
38.1 (37.3–38.9)
32.8 (32.3–33.4)

95.0 (94.3–95.8)
99.0 (98.8–99.3)
98.7 (98.3–99.0)
97.7 (97.4–98.1)
93.9 (93.1–94.7)
90.3 (88.8–91.8)
98.1 (97.7–98.5)
96.9 (96.5–97.4)
92.8 (92.2–93.3)

5132
29 349
13 530
13 810
13 265
26 688
9281
13 357
14 220
17 257
13 197
14 549
56 307
19 074
23 240
16 780
13 498
10 847
29 972
17 996

2.7
1.4
1.2
0.8
0.7
1.4
0.9
1.6
0.7
0.5
1.0
0.8
1.1
1.4
1.9
1.0
1.2
1.7
0.7
0.5

38.2 (36.8–39.5)
32.7 (32.1–33.2)
32.8 (32.0–33.6)
31.6 (30.8–32.4)
29.4 (28.6–30.2)
40.0 (39.4–40.6)
29.2 (28.3–30.1)
40.2 (39.4–41.1)
21.9 (21.3–22.6)
18.1 (17.5–18.6)
30.5 (29.7–31.3)
37.1 (36.3–37.9)
25.0 (24.7–25.4)
56.4 (55.7–57.1)
40.0 (39.4–40.6)
28.5 (27.8–29.2)
30.1 (29.4–30.9)
39.5 (38.5–40.4)
22.7 (22.2–23.1)
23.3 (22.7–23.9)

96.0 (95.1–96.9)
97.5 (97.2–97.8)
97.3 (96.8–97.7)
97.1 (96.6–97.6)
97.8 (97.3–98.2)
98.5 (98.3–98.7)
96.9 (96.3–97.6)
98.2 (97.8–98.5)
97.5 (96.9–98.0)
94.2 (93.4–95.0)
97.5 (97.0–98.0)
96.4 (95.9–96.9)
97.1 (96.8–97.3)
99.2 (99.0–99.4)
97.2 (96.8––97.5)
98.3 (98.0–98.7)
95.9 (95.3–96.5)
96.5 (96.0–97.1)
97.2 (96.9–97.6)
97.8 (97.3–98.2)

40 221
22 768
54 913
17 622
16 795
16 692

2.9
1.9
1.6
2.3
1.1
5.3

33.8 (33.4–34.3)
35.0 (34.4–35.6)
42.9 (42.5–43.3)
53.0 (52.3–53.8)
32.3 (31.6–33.0)
59.1 (58.4–60.0)

90.9 (90.4–91.4)
98.6 (98.3–98.9)
93.0 (92.6–93.2)
98.8 (98.6–99.1)
98.0 (97.6–98.4)
86.0 (85.3–86.7)

8871

1.2

13.5 (12.8–14.2)

97.3 (96.4–98.2)

10 621

3.0

25.6 (24.8–26.4)

96.5 (95.8–97.2)

3543

1.2

23.1 (21.7–24.5)

99.5 (99.0–100)

22 721

0.7

24.5 (23.9–25.0)

98.6 (98.3–98.9)

732 844

1.5

32.4 (29.3–35.6)

96.5 (95.9–97.2)

Downloaded from https://academic.oup.com/inthealth/article/12/5/388/5680313 by Serials Acquisitions Edith Cowan University, Library-Level 2 user on 14 September 2021

Table 1. Prevalence of medical injection and access to sterile injection equipment by country
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Results
The DHS reports for 39 countries met the inclusion criteria for
this study and were meta-analysed (see Table 1). The pooled 12month prevalence estimate of medical injection among adults
15–49 y of age in LMICs was 32.4% (95% conﬁdence interval [CI] 29.3–35.6) (see Figure 2). Medical injections were more
common in Pakistan, Rwanda and Myanmar, with prevalence
estimates of 59.1% (95% CI 58.4–60.0), 56.4% (95% CI 55.7–
57.1) and 53.0% (95% CI 52.3–53.8), respectively (Table 1). The
sensitivity analysis performed by excluding data from Pakistan
yielded a prevalence estimate of 31.7% (95% CI 28.8–34.7).
This estimate was comparable to the overall pooled estimate.
There were substantial regional variations in the 12-month prevalence of medical injection, ranging from 13.5 (95% CI 12.8–14.2)
in West Asia to 42.7% (95% CI 35.0–50.4) in the South and
Southeast Asia.
Overall, 96.5% (95% CI 95.9–97.2) of individuals reported
having an injection with a syringe and needle taken from a
new, unopened package. Access to new syringes and needles
was comparatively less common in Pakistan, Comoros and
Afghanistan, with estimates of 86.0% (95% CI 85.3–86.7), 90.3%
(95% CI 88.8–91.8) and 90.9% (95% CI 90.4–91.4), respectively
(Table 1). There were also regional differences in access to sterile
injection devices (Table 2), with Latin America and the Caribbean
having the highest regional estimate of 99.0% (95% CI 98.2–
99.9) and South and Southeast Asia having the lowest estimate
(94.2% [95% CI 91.1–97.3]).
Based on age categorization (Table 2), we found the highest
prevalence of injection medication use among adults aged 25–
29 y (37.0% [95% CI 33.4–40.5]) and the lowest among adults
aged 40–49 y (30.4% [95% CI 27.0–33.8]). Adults in the highest
wealth index category had a higher prevalence of injection medication use (35.3% [95% CI 32.1–38.4]) than their counterparts
in the lowest wealth index category (28.5% [95% CI 25.1–31.9]).
This pattern of results for the wealth index was similarly observed

for education level, where adults with at least a secondary education had a higher prevalence of injection use (35.1% [95% CI
31.9–38.2]) than those without education (29.1% [95% CI 25.8–
32.3]). Interestingly, the highest prevalence of access to sterile
injection equipment was also recorded for adults in the highest
wealth index category (97.4% [95% CI 96.9–97.8]) compared
with those in the lowest wealth index category (95.2% [95% CI
94.2–96.3]), as well as adults with secondary/higher education
level (97.4% [95% CI 96.9–97.9]) compared with those with no
education (94.7% [95% CI 93.6–95.9]).

Discussion
In this study we estimated the prevalence of medical injections
and assessed the level of access to sterile injection equipment
in LMICs (potentially safe injections). The pooled prevalence of
medical injections was 32.4%. Higher prevalences were recorded
in South/Southeast Asia and sub-Saharan Africa regions. Pakistan, Rwanda and Myanmar were the countries with the highest
prevalence of medical injection use. The pooled and disaggregated prevalence found in our study indicates that medical injections were considerably common in LMICs—suggesting varying
degrees of overuse of this mode of drug administration in the
countries assessed. Overall, 96.5% of adults in LMICs had access
to new, unopened syringes and needles. Thus 3.5%, approximately 1 in 29, medical injections were potentially unsafe in
LMICs.
The global prevalence of unsafe injection was estimated in
the year 2010 to be 5%.2,5 Our estimated pooled prevalence is
lower than this global prevalence—probably suggesting some
progress over time. However, given the risk associated (morbidity
and mortality) with unsafe injections,1,2,6–8,11,12 our estimated
pooled prevalence is considerable and calls for urgent actions/interventions. This position becomes even more important in
countries such as Pakistan, Comoros and Afghanistan, where we
found 14.0%, 9.7% and 9.1% prevalence of potentially unsafe
medical injections, respectively.
Generally, both patient- and provider-related factors are
known to drive overuse and subsequently unsafe medical
injections.3,17,18 For example, injection medications are often
thought (by patients and healthcare providers alike) to be
better, more effective or stronger than oral medicines.3,18
This observation, coupled with the proﬁteering tendencies of
some healthcare providers, may be relevant in explaining the
considerably high prevalence of medical injection found in the
present study. Poor knowledge of the risks associated with the
overuse of injections, sociocultural beliefs, ﬁnancial constraints,
poor consumer protection, low awareness in the population and
poor regulation of medical practices have equally been noted to
contribute to the overuse of injection medications.3,17,18
The ﬁnding of a high prevalence of medical injections in
South/Southeast Asian countries is probably not surprising.
Available data have shown that injections are commonly used in
countries in these regions.17 For instance, in Pakistan (where we
found the highest prevalence of medical injections and unsafe
injections), and indeed in other countries in the South/Southeast
Asia region, economic incentives, patient preference (due to
misconceptions about injections), private practice (in particular)
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classiﬁed countries into low income or middle income using the
World Bank income classiﬁcation system.
We employed a random effects meta-analysis to calculate
the pooled prevalence estimates of medical injection and
access to sterile injection equipment. We used a random effects
meta-analysis because it allows for heterogeneity across studies.
Our study population differs along geographic, regional and
socio-economic divides. Hence, even though the DHS used a similar study design across countries, we expected heterogeneity.
Our choice of a random effects model was equally supported by
a test of heterogeneity of the DHS data obtained for the different
countries, which showed a high level of inconsistency (I2 >50%).
Furthermore, we used sensitivity analysis to assess the effects
of outliers as well as test the robustness of our ﬁndings. We
performed a sensitivity analysis by excluding from our analysis
data from one country at a time, and the impact of excluding the
data was evaluated on the summary results.
We performed subgroup analyses to estimate the prevalence
of medical injection and access to sterile injection equipment by
some sociodemographic factors, including sex, age, type of residence, wealth index, education, geographic region and income
classiﬁcation.

E. O. Adewuyi and A. Auta

and prescribing by unqualiﬁed practitioners are among the major
factors contributing to the overuse of medical injections.17,19
Interventions, including regulatory and policy measures, directed
at these factors may contribute to reducing the overuse of
medical injections in this region and, by extension, other LMICs.

392

Our study reveals the place of the wealth index and education
level in medical injection medication use as well as in the level of
access to sterile injection equipment (potentially safe injection).
Rich respondents had a higher prevalence of medical injections
compared with the poor. Given that injections generally tend to
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Figure 2. Meta-analysis for the prevalence of medical injection in low- and middle-income countries.

International Health

Category

Sex
Male
Female
Age (y)a
15–24
25–29
30–39
40–49
Type of residencea
Urban
Rural
Education levela
No education
Primary
Secondary or higher
Wealth index
Lowest
Second
Middle
Fourth
Highest
Geographic region
Sub-Saharan Africa
Latin America and Caribbean
West Asia
Central Asia
South and Southeast Asia
Country income level
Low income
Middle income
Overall
a Category

Number of participants
(N=732 844)

Prevalence of medical injection,
% (95% CI)

Access to sterile syringes and
needles, % (95% CI)

218 991
513 853

27.1 (24.3–29.9)
35.3 (31.8–38.7)

96.4 (95.8–97.0)
96.6 (95.9–97.2)

267 732
125 606
199 956
138 252

30.7 (27.8–33.7)
37.0 (33.4–40.5)
34.3 (30.9–37.7)
30.4 (27.0–33.8)

96.5 (95.9–97.1)
96.9 (96.3–97.5)
96.7 (96.0–97.3)
96.2 (95.4–97.0)

286 943
444 367

34.2 (31.2–37.2)
31.8 (28.4–35.2)

97.1 (96.6–97.6)
96.0 (95.3–96.8)

202 271
216 224
303 658

29.1 (25.8–32.3)
33.0 (29.5–36.4)
35.1 (31.9–38.2)

94.7 (93.6–95.9)
96.5 (95.9–97.1)
97.4 (96.9–97.9)

125 962
135 289
141 767
155 385
174 441

28.5 (25.1–31.9)
31.2 (27.8–34.6)
32.6 (29.2–36.0)
34.2 (31.1–37.4)
35.3 (32.1–38.4)

95.2 (94.2–96.3)
96.2 (95.4–97.0)
96.4 (95.7–97.1)
97.0 (96.5–97.6)
97.4 (96.9–97.8)

518 077
26 264
8871
10 621
169 011

31.8 (28.6–34.9)
23.9 (22.5–25.3)
13.5 (12.8–14.2)
25.6 (24.8–26.4)
42.7 (35.0–50.4)

96.9 (96.4–97.3)
99.0 (98.2–99.9)
97.3 (96.4–98.2)
96.5 (95.8–97.2)
94.2 (91.1–97.3)

386 292
346 552
732 844

31.4 (27.5–35.4)
33.6 (28.4–38.7)
32.4 (29.3–35.6)

96.4 (95.6–97.2)
96.7 (95.7–97.8)
96.5 (95.9–97.2)

with some missing data.

be more expensive than oral medicines, this ﬁnding may well be
explained by the differences in ﬁnancial capabilities, as in many
LMIC settings, healthcare services are paid for out of pocket.20,21
Not surprisingly, the rich also had greater access to sterile injection equipment compared with their poor counterparts, highlighting the possible disparity in access to quality healthcare that
is commonly reported between the rich and the poor.22–24 These
ﬁndings coupled with those in respect of education level suggest
that quality healthcare in many developing countries continues
to be associated with socio-economic level. A holistic approach to
safer injection thus needs to address socio-economic disparities
in access to quality healthcare services.
The use of nationally representative DHS data is the major
strength of this study; thus our ﬁndings are generalizable to the
adult population ages 15–49 y in the LMICs assessed in this
study. The application of a meta-analysis in providing pooled and
disaggregated estimates remains another important strength.

However, non-availability of relevant DHS data for our study
period (2010–2017) limited the number of LMICs considered in
the present study. Also, given that the DHS data largely captured
adults 15–49 y of age (an age group with lesser healthcare
needs compared with older adults), medical injection use may
have been underestimated. The data analysed were self-reported
and collected retrospectively, hence recall and social desirability
biases are likely. Nonetheless, restricting our analysis to information provided for the period within 1 y preceding the surveys may
reduce the chances of recall bias.

Conclusions
Our study reveals a substantially high prevalence of medical
injection in LMICs, indicating that overuse of medical injection remains a considerable public health challenge in these
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Table 2. Prevalence of medical injection and access to new syringes and needles by demographic category
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countries. This overuse varies from region to region and from
one country to another, with Pakistan, Rwanda and Myanmar
ranking as countries where this was most commonly practised.
About 1 in 29 injections in LMICs is potentially unsafe. Urgent,
comprehensive and multisectoral interventions, including regulation of medical practices and policy measures aimed at
addressing socio-economic disparities in access to healthcare
services, are needed to stem the tide of unnecessary and unsafe
medical injection use in LMICs. In addition, there is a need to
educate both healthcare workers and patients on the dangers of
unsafe injection and the need for medical injection to be given
only when absolutely necessary. This is particularly critical in
countries/regions with a high prevalence of unsafe injection use
as found in the present study.

